Edition:
United Kingdom

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

174.23USD
8:36pm BST
Change (% chg)

$2.29 (+1.33%)
Prev Close
$171.94
Open
$173.66
Day's High
$175.44
Day's Low
$170.38
Volume
1,184,330
Avg. Vol
1,644,740
52-wk High
$201.23
52-wk Low
$152.16

Select another date:

BRIEF-Amgen Says In April, Co's Board Increased The Amount Authorized Under Co's Stock Repurchase Program By An Additional $5 Bln - SEC Filing

* AMGEN INC SAYS IN APRIL, CO'S BOARD INCREASED THE AMOUNT AUTHORIZED UNDER CO'S STOCK REPURCHASE PROGRAM BY AN ADDITIONAL $5.0 BILLION - SEC FILING Source text: (https://bit.ly/2FftYIV) Further company coverage:

UPDATE 3-Amgen expects strong demand for new migraine prevention drug

April 24 Amgen Inc on Tuesday reported a higher first-quarter profit, as sales rose 3 percent - a trend it expects to accelerate as it launches new drugs like migraine treatment Aimovig, likely to get U.S. approval next month.

Amgen posts higher first-quarter profit as sales rise 3 percent

Amgen Inc on Tuesday reported a higher first-quarter profit, driven by lower taxes and a 3 percent increase in product sales as growth for newer drugs like cholesterol medication Repatha offset weakness in older products.

RPT-Amgen posts higher 1st-quarter profit as sales rise 3 percent

April 24 Amgen Inc on Tuesday reported a higher first quarter profit, driven by lower taxes and a 3 percent increase in product sales as strong growth for newer drugs like cholesterol medication Repatha offset weakness in older products.

Amgen posts higher 1st-quarter profit as sales rise 3 percent

April 24 Amgen Inc on Tuesday reported a higher first quarter profit, driven by lower taxes and a 3 percent increase in product sales as strong growth for newer drugs like cholesterol medication Repatha offset weakness in older products.

Express Scripts targets Amgen, Lilly migraine drugs in pricing shift

LOS ANGELES The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc, Eli Lilly and Co and other makers of new migraine medicines to try and fix it.

Express Scripts targets Amgen, Lilly migraine drugs in pricing shift

LOS ANGELES The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc , Eli Lilly and Co and other makers of new migraine medicines to try and fix it.

FOCUS-Express Scripts targets Amgen, Lilly migraine drugs in pricing shift

LOS ANGELES, April 24 The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc, Eli Lilly and Co and other makers of new migraine medicines to try and fix it.

RPT-FOCUS-Express Scripts targets new migraine drugs to change U.S. pricing dynamic

LOS ANGELES, April 24 The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc and other makers of new migraine medicines to try and fix it.

FOCUS-Express Scripts targets new migraine drugs to change U.S. pricing dynamic

LOS ANGELES, April 24 The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc and other makers of new migraine medicines to try and fix it.

Select another date: